Topiramate for the Treatment of Methamphetamine Dependence - 1
NCT ID: NCT00345371
Last Updated: 2017-03-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
140 participants
INTERVENTIONAL
2006-04-30
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Trial of Topiramate for Cocaine Addiction
NCT00685178
A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence
NCT01354470
Effectiveness of Topiramate in Treating Cocaine Dependent Individuals - 1
NCT00249691
Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence
NCT00687713
Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence
NCT00520286
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Topiramate
Subjects will receive topiramate (in tablet form) up to 200 mg/day for 13 weeks.
Topiramate
Placebo Oral Tablet
After randomization subjects will receive topiramate matched placebo (in tablet form), up to 200 mg/day for 13 weeks.
Placebo Oral Tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Topiramate
Placebo Oral Tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be able to proved written informed consent
* Must have a body mass index greater than 18 kg/m(2)
* Must meet DSM-IV criteria for methamphetamine dependence
* Must currently be using methamphetamine as confirmed by a positive urine test over the past 14 days
* If female of child bearing potential, must agree to use birth control
Exclusion Criteria
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bankole Johnson
Role: PRINCIPAL_INVESTIGATOR
VA Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Matrix Institute on Addictions
Costa Mesa, California, United States
South Bay Treatment Center
San Diego, California, United States
Torrance Site
Torrance, California, United States
John A. Burns School of Medicine
Honolulu, Hawaii, United States
Powell Chemical Dependency Center
Des Moines, Iowa, United States
University of Missouri - Kansas City
Kansas City, Missouri, United States
Salt Lake City VA Medical Center
Salt Lake City, Utah, United States
UVA CARE
Charlottesville, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Elkashef A, Kahn R, Yu E, Iturriaga E, Li SH, Anderson A, Chiang N, Ait-Daoud N, Weiss D, McSherry F, Serpi T, Rawson R, Hrymoc M, Weis D, McCann M, Pham T, Stock C, Dickinson R, Campbell J, Gorodetzky C, Haning W, Carlton B, Mawhinney J, Li MD, Johnson BA. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction. 2012 Jul;107(7):1297-306. doi: 10.1111/j.1360-0443.2011.03771.x. Epub 2012 Feb 28.
Li MD, Wang J, Niu T, Ma JZ, Seneviratne C, Ait-Daoud N, Saadvandi J, Morris R, Weiss D, Campbell J, Haning W, Mawhinney DJ, Weis D, McCann M, Stock C, Kahn R, Iturriaga E, Yu E, Elkashef A, Johnson BA. Transcriptome profiling and pathway analysis of genes expressed differentially in participants with or without a positive response to topiramate treatment for methamphetamine addiction. BMC Med Genomics. 2014 Dec 12;7:65. doi: 10.1186/s12920-014-0065-x.
Related Links
Access external resources that provide additional context or updates about the study.
Link to abstract
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIDA-CSP-1025-1
Identifier Type: -
Identifier Source: org_study_id
NCT00431652
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.